{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:51:06Z","timestamp":1787028666607,"version":"build-2736575974"},"reference-count":29,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2026,2,22]],"date-time":"2026-02-22T00:00:00Z","timestamp":1771718400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background: Poly(ADP-ribose) polymerase (PARP) inhibitors have been established as a first-line maintenance therapy in advanced epithelial ovarian cancer (EOC) following platinum-based chemotherapy. While phase III trials have demonstrated significant progression-free survival (PFS) benefits with olaparib and niraparib, real-world data remain limited. Methods: This retrospective, multicenter real-world study included 179 patients with newly diagnosed epithelial ovarian treated with first-line maintenance olaparib or niraparib across 33 centers in T\u00fcrkiye between January 2014 and March 2025. Clinical, pathological, and molecular data\u2014including BRCA (Breast Cancer Susceptibility Gene) mutation status, origin, and variant classification\u2014was collected. The primary endpoint was PFS, and secondary endpoints included overall survival (OS) and safety. Survival outcomes were analyzed using Kaplan\u2013Meier methods. Results: Of 179 patients, 110 received olaparib and 69 received niraparib. BRCA mutations were present in 88.3% of patients, while 11.7% had unknown HRD status. Median follow-up was 16.5 months, and median PFS was not reached. Estimated PFS rates for the overall cohort were 91.0% at 6 months, 83.0% at 12 months, and 64.0% at 24 months. In the olaparib cohort, BRCA-mutant patients demonstrated PFS rates of 89%, 78%, 73%, and 64% at 6, 12, 18, and 24 months, respectively. In the niraparib cohort, corresponding PFS rates among BRCA-mutant patients were 87% at 6 months and 75% at 12 months. Patients harboring pathogenic BRCA variants experienced longer PFS compared with those with likely pathogenic variants. Any-grade adverse events occurred in 73.7% of patients, and grade 3\u20134 events in 29.6%, with hematologic toxicities predominating. Dose interruptions were more frequent with niraparib, while treatment discontinuation rates were low in both groups. No cases of myelodysplastic syndrome or acute myeloid leukemia were observed. Conclusions: In this large multicenter real-world cohort, first-line maintenance therapy with olaparib and niraparib provided durable PFS benefit in patients with advanced EOC, particularly among those with pathogenic BRCA mutations, confirming their effectiveness and manageable safety profiles in routine clinical practice.<\/jats:p>","DOI":"10.3390\/jcm15041657","type":"journal-article","created":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T08:58:21Z","timestamp":1771837101000},"page":"1657","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Outcomes of First-Line PARP Inhibitor Therapy in Ovarian Cancer: A Multicenter Retrospective Analysis"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0418-5749","authenticated-orcid":false,"given":"Baris","family":"Koksal","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Hacettepe University Faculty of Medicine, 06100 Ankara, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3060-377X","authenticated-orcid":false,"given":"Hasan Cagri","family":"Yildirim","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Ege University Faculty of Medicine, 35100 Izmir, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6924-9467","authenticated-orcid":false,"given":"Deniz Can","family":"Guven","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Hacettepe University Faculty of Medicine, 06100 Ankara, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0156-5973","authenticated-orcid":false,"given":"Fatih","family":"Kose","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Baskent University Adana Kisla Hospital, 01120 Adana, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3930-9059","authenticated-orcid":false,"given":"Gorkem","family":"Koymen","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Izmir City Hospital, 35330 Izmir, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ozlem","family":"Ozdemir","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Izmir City Hospital, 35330 Izmir, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ugur","family":"Ozberk","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Numune Training and Research Hospital, 06230 Ankara, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8917-9267","authenticated-orcid":false,"given":"Efnan","family":"Algin","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Numune Training and Research Hospital, 06230 Ankara, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Murad","family":"Guliyev","sequence":"additional","affiliation":[{"name":"Cerrahpasa Faculty of Medicine, Department of Medical Oncology, Istanbul University-Cerrahpasa, 34098 Istanbul, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nebi Serkan","family":"Demirci","sequence":"additional","affiliation":[{"name":"Cerrahpasa Faculty of Medicine, Department of Medical Oncology, Istanbul University-Cerrahpasa, 34098 Istanbul, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6635-2012","authenticated-orcid":false,"given":"Ozkan","family":"Alan","sequence":"additional","affiliation":[{"name":"Cerrahpasa Faculty of Medicine, Department of Medical Oncology, Istanbul University-Cerrahpasa, 34098 Istanbul, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-3897-3055","authenticated-orcid":false,"given":"Ahmet","family":"Baklaci","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Aydin Adnan Menderes University Faculty of Medicine, 09100 Aydin, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4380-9419","authenticated-orcid":false,"given":"Bilgin","family":"Demir","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Aydin Adnan Menderes University Faculty of Medicine, 09100 Aydin, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-2802-5799","authenticated-orcid":false,"given":"Ozlem","family":"Topkaya","sequence":"additional","affiliation":[{"name":"Anadolu Medical Center, Department of Medical Oncology, 41400 Kocaeli, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Necdet","family":"Uskent","sequence":"additional","affiliation":[{"name":"Anadolu Medical Center, Department of Medical Oncology, 41400 Kocaeli, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kadriye Bir","family":"Yucel","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Gazi University Faculty of Medicine, 06560 Ankara, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Orhun","family":"Akdogan","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Gazi University Faculty of Medicine, 06560 Ankara, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4462-6393","authenticated-orcid":false,"given":"Bahadir","family":"Koylu","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Koc University Hospital, 34010 Istanbul, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatih","family":"Selcukbiricik","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Koc University Hospital, 34010 Istanbul, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1154-5850","authenticated-orcid":false,"given":"Irem","family":"Bilgetekin","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Memorial Ankara Hospital, 06520 Ankara, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaan","family":"Helvaci","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Memorial Ankara Hospital, 06520 Ankara, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmet","family":"Unal","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dokuz Eylul University Faculty of Medicine, 35340 Izmir, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huseyin Salih","family":"Semiz","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dokuz Eylul University Faculty of Medicine, 35340 Izmir, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teoman","family":"Sakalar","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Kahramanmaras Sutcu Imam University Faculty of Medicine, 46100 Kahramanmaras, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7312-3827","authenticated-orcid":false,"given":"Nadiye","family":"Sever","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Marmara University Pendik Training and Research Hospital, 34890 Istanbul, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9140-1453","authenticated-orcid":false,"given":"Ceren Mordag","family":"Cicek","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Pamukkale University Faculty of Medicine, 20070 Denizli, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8142-0362","authenticated-orcid":false,"given":"Gamze Gokoz","family":"Dogu","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Pamukkale University Faculty of Medicine, 20070 Denizli, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1053-0668","authenticated-orcid":false,"given":"Sedat","family":"Biter","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Cukurova University Faculty of Medicine, 01330 Adana, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ertugrul","family":"Bayram","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Cukurova University Faculty of Medicine, 01330 Adana, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Canan","family":"Yildiz","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Afyonkarahisar University of Health Sciences, 03200 Afyonkarahisar, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hacer","family":"Demir","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Afyonkarahisar University of Health Sciences, 03200 Afyonkarahisar, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ismail","family":"Bayrakci","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Trakya University Faculty of Medicine, 22030 Edirne, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2158-3490","authenticated-orcid":false,"given":"Bulent","family":"Erdogan","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Trakya University Faculty of Medicine, 22030 Edirne, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehmet Emin","family":"Kalender","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, MEDDEM Hospital, 32200 Isparta, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8310-1752","authenticated-orcid":false,"given":"Halil Goksel","family":"Guzel","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Antalya Training and Research Hospital, 07050 Antalya, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0290-8787","authenticated-orcid":false,"given":"Banu","family":"Ozturk","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Antalya Training and Research Hospital, 07050 Antalya, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5357-7610","authenticated-orcid":false,"given":"Berkan","family":"Karabuga","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Ankara Oncology Training and Research Hospital, 06200 Ankara, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ozturk","family":"Ates","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Ankara Oncology Training and Research Hospital, 06200 Ankara, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emine Bihter","family":"Cetin","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Manisa Celal Bayar University Faculty of Medicine, 45030 Manisa, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1857-593X","authenticated-orcid":false,"given":"Mustafa","family":"Sahbazlar","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Manisa Celal Bayar University Faculty of Medicine, 45030 Manisa, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Inal","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Mersin City Training and Research Hospital, 33090 Mersin, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veli","family":"Sunar","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, LOSANTE Children and Adult Hospital, 06520 Ankara, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatma Bugdayci","family":"Basal","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, LOSANTE Children and Adult Hospital, 06520 Ankara, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3030-2475","authenticated-orcid":false,"given":"Esra","family":"Asik","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Karadeniz Technical University Faculty of Medicine, 61080 Trabzon, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atila","family":"Yildirim","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Karadeniz Technical University Faculty of Medicine, 61080 Trabzon, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nejat Emre","family":"Oksuz","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Ankara University Faculty of Medicine, 06230 Ankara, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuksel","family":"Urun","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Ankara University Faculty of Medicine, 06230 Ankara, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erdinc","family":"Nayir","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, VM Medical Park Hospital, Toros University, 33200 Mersin, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9040-7266","authenticated-orcid":false,"given":"Sema","family":"Turker","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, VM Medical Park Maltepe Hospital, 34844 Istanbul, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1461-7485","authenticated-orcid":false,"given":"Sercan","family":"On","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Ege University Faculty of Medicine, 35100 Izmir, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9753-8517","authenticated-orcid":false,"given":"Ali","family":"Aytac","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Sanliurfa Mehmet Akif Inan Training and Research Hospital, 63050 Sanliurfa, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serkan","family":"Menekse","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Manisa City Hospital, 45040 Manisa, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1268-6666","authenticated-orcid":false,"given":"Yasemin Bakkal","family":"Temi","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Kocaeli University Faculty of Medicine, 41380 Kocaeli, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazim","family":"Uygun","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Kocaeli University Faculty of Medicine, 41380 Kocaeli, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1976-3951","authenticated-orcid":false,"given":"Elif","family":"Sahin","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Kocaeli City Hospital, 41090 Kocaeli, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3342-3144","authenticated-orcid":false,"given":"Merve","family":"Keskinkilic","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Izmir Buca Seyfi Demirsoy Training and Research Hospital, 35390 Izmir, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zafer","family":"Arik","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Hacettepe University Faculty of Medicine, 06100 Ankara, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,2,22]]},"reference":[{"key":"ref_1","first-page":"17","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","unstructured":"National Cancer Institute (2025, July 20). Ovarian Cancer\u2014Cancer Stat Facts, Available online: https:\/\/seer.cancer.gov\/statfacts\/html\/ovary.html."},{"key":"ref_3","unstructured":"American Cancer Society (2025, July 20). Ovarian Cancer Statistics. Available online: https:\/\/www.cancer.org\/cancer\/types\/ovarian-cancer\/about\/key-statistics.html."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"385","DOI":"10.4143\/crt.2023.447","article-title":"Cancer statistics in Korea: Incidence, mortality, survival, and prevalence in 2020","volume":"55","author":"Kang","year":"2023","journal-title":"Cancer Res. Treat."},{"key":"ref_5","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"ref_6","first-page":"284","article-title":"Ovarian cancer statistics, 2018","volume":"68","author":"Torre","year":"2018","journal-title":"CA Cancer J. Clin."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1093\/annonc\/mdz062","article-title":"ESMO\u2013ESGO consensus conference recommendations on ovarian cancer","volume":"30","author":"Colombo","year":"2019","journal-title":"Ann. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"vi24","DOI":"10.1093\/annonc\/mdt333","article-title":"Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO clinical practice guidelines","volume":"24","author":"Ledermann","year":"2013","journal-title":"Ann. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"38","DOI":"10.7150\/jca.49406","article-title":"Current ovarian cancer maintenance strategies and new developments","volume":"12","author":"Gogineni","year":"2021","journal-title":"J. Cancer"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/s13048-022-01020-1","article-title":"Maintenance therapy for newly diagnosed epithelial ovarian cancer","volume":"15","author":"Nag","year":"2022","journal-title":"J. Ovarian Res."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"3468","DOI":"10.1200\/JCO.20.01924","article-title":"PARP inhibitors in the management of ovarian cancer: ASCO guideline","volume":"38","author":"Tew","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.soncn.2019.02.001","article-title":"Ovarian cancer: An integrated review","volume":"35","author":"Stewart","year":"2019","journal-title":"Semin. Oncol. Nurs."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1056\/NEJMoa1910962","article-title":"Niraparib in patients with newly diagnosed advanced ovarian cancer","volume":"381","author":"Pothuri","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"S50","DOI":"10.1016\/S0090-8258(22)01298-7","article-title":"Efficacy and safety of niraparib as maintenance treatment in patients with newly diagnosed advanced ovarian cancer using an individualized starting dose (PRIME Study): A randomized, double-blind, placebo-controlled, phase 3 trial (LBA 5)","volume":"166","author":"Li","year":"2022","journal-title":"Gynecol Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1056\/NEJMoa1810858","article-title":"Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer","volume":"379","author":"Moore","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Jiang, Y., Zhao, J., Zhang, L., Tian, S., Yang, T., Wang, L., Zhao, M., Yang, Q., Wang, Y., and Yang, X. (2020). Efficacy and safety of PARP inhibitors in advanced-stage epithelial ovarian cancer. Front. Oncol., 10.","DOI":"10.3389\/fonc.2020.00954"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1016\/j.annonc.2020.06.004","article-title":"The forefront of ovarian cancer therapy: Update on PARP inhibitors","volume":"31","author":"Mirza","year":"2020","journal-title":"Ann. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1056\/NEJMoa1911361","article-title":"Olaparib plus bevacizumab as first-line maintenance","volume":"381","author":"Pautier","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1136\/ijgc-2022-004149","article-title":"Poly (ADP-ribose) polymerase inhibitors (PARPi) in ovarian cancer: Lessons learned and future directions","volume":"33","author":"Caruso","year":"2023","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1200\/JCO.22.01549","article-title":"Overall survival with maintenance olaparib at 7-year follow-up (SOLO1)","volume":"41","author":"DiSilvestro","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.annonc.2023.05.005","article-title":"Olaparib plus bevacizumab first-line maintenance: Final OS results of PAOLA-1","volume":"34","author":"Leary","year":"2023","journal-title":"Ann. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"3952","DOI":"10.1200\/JCO.22.01003","article-title":"A Randomized, Phase III Trial to Evaluate Rucaparib Monotherapy as Maintenance Treatment in Patients With Newly Diagnosed Ovarian Cancer (ATHENA\u2013MONO\/GOG-3020\/ENGOT-ov45)","volume":"40","author":"Monk","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"112908","DOI":"10.1016\/j.ejca.2023.04.024","article-title":"Progression-free survival and safety at 3.5 years of follow-up: Results from the randomised phase 3 PRIMA\/ENGOT-OV26\/GOG-3012 trial of niraparib maintenance treatment in patients with newly diagnosed ovarian cancer","volume":"189","author":"Pothuri","year":"2023","journal-title":"Eur. J. Cancer"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/j.annonc.2024.08.2241","article-title":"Niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer: Final overall survival results from the PRIMA\/ENGOT-OV26\/GOG-3012 trial","volume":"35","author":"Monk","year":"2024","journal-title":"Ann. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1001\/jamaoncol.2023.2283","article-title":"Treatment with Niraparib Maintenance Therapy in Patients with Newly Diagnosed Advanced Ovarian Cancer: A Phase 3 Randomized Clinical Trial","volume":"9","author":"Li","year":"2023","journal-title":"JAMA Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1158\/1535-7163.MCT-20-1064","article-title":"Real-world experience of olaparib treatment in patients with ovarian cancer: A Chinese multicenter study","volume":"20","author":"Zheng","year":"2021","journal-title":"Mol. Cancer Ther."},{"key":"ref_27","first-page":"e1180","article-title":"Real-world clinical outcomes of olaparib therapy in Chinese patients with advanced serous ovarian cancer treated in Macau","volume":"2","author":"Cao","year":"2019","journal-title":"Cancer Rep."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"4603","DOI":"10.21873\/anticanres.15273","article-title":"Real-world experience of niraparib in newly-diagnosed epithelial ovarian cancer","volume":"41","author":"Shin","year":"2021","journal-title":"Anticancer Res."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1336616","DOI":"10.3389\/fonc.2024.1336616","article-title":"PARP inhibitor maintenance treatment for newly diagnosed ovarian cancer patients: A real-world study from China","volume":"14","author":"Chen","year":"2024","journal-title":"Front Oncol."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/4\/1657\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T09:21:09Z","timestamp":1771838469000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/4\/1657"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,22]]},"references-count":29,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,2]]}},"alternative-id":["jcm15041657"],"URL":"https:\/\/doi.org\/10.3390\/jcm15041657","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,22]]}}}